Medicine containing nitric oxide synthase inhibitor for treating diabetes

Abstract

The present invention relates to a medicine containing nitrogen monoxide synthase inhibitor for curing diabetes. Said inhibitor comprises aminoguanidine and n-monomethyl arginine, also includes diluting agent, filling agent, disintegrating agent, moistening agent, lubricating agent, aromatic substance, color developing agent and other conventional agent. Said invention can be made into any one pharmaceutically-acceptable form, and the tests show that said inhibitor can delay or prevent the development of non-insulin-dependent diabetes from hyperproinsulinemia to patent diabetes.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to diabetes, and specifically to a drug for treating diabetes containing nitric oxide synthase inhibitors. Background technique: [0002] Diabetes is the most common metabolic disorder in humans. It is divided into insulin-dependent diabetes and insulin-independent diabetes. Both types of diabetes will damage the body's ability to use glucose as energy. Chronic high blood sugar will slowly damage many tissues and organs of the body. organ. Although insulin can be used to treat diabetes, diabetes remains a serious disease responsible for much death and morbidity worldwide. The consequences of long-term diabetes can include eye damage, often leading to blindness, circulatory problems, wound healing problems, and other serious consequences. Non-insulin-dependent diabetes mellitus is a form of diabetes that occurs primarily in adults who have an adequate supply of insulin but have deficits in...

AI Technical Summary

Problems solved by technology

[0003] The mechanism of action of oral antidiabetic drugs in the prior art (such as commonly used sulfonylureas) is mainly based on increasing the release of insulin from the β cells of the pancreas, which may lead to accelerated consumption of endogenously produced insulin in diabetic patients in the long run, The modern view of the pathobiochemistry of diabetes onset in adulthood thus emphasizes the need to treat peripheral insulin resistance in this setting